CO5261637A1 - MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE - Google Patents

MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE

Info

Publication number
CO5261637A1
CO5261637A1 CO01010963A CO01010963A CO5261637A1 CO 5261637 A1 CO5261637 A1 CO 5261637A1 CO 01010963 A CO01010963 A CO 01010963A CO 01010963 A CO01010963 A CO 01010963A CO 5261637 A1 CO5261637 A1 CO 5261637A1
Authority
CO
Colombia
Prior art keywords
progestin
formulation according
formulation
dose
sufficient
Prior art date
Application number
CO01010963A
Other languages
Spanish (es)
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Schillinger
Schillinger Ekkerhard
Habenicht Ursula-Fried
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO5261637A1 publication Critical patent/CO5261637A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación anticonceptiva masculina CARACTERIZADA PORQUE comprende una cantidad eficaz de una progestina, donde dicha progestina posee propiedades tanto androgénicas como estrogénicas. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE la progestina es noretisterona (NET) o sus derivados, tales como sus ésteres carboxílicos, en particular su acetato o su enantato. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE los niveles de dicha progestina son suficientes como para suprimir la espermatogénesis. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE los niveles de dicha progestina son suficientes como para inducir la oligozoospermia o la azoospermia. Una formulación de acuerdo con la reivindicación 2 CARACTERIZADA PORQUE la dosis del derivado de NET está entre 1 y 10 mg, tal como 1, 2, 3, 4, 5, 6, 7, 8, 9 ó 10 mg. Una formulación de acuerdo con la reivindicación 2 CARACTERIZADA PORQUE la dosis del derivado de NET corresponde a una dosis de 100 a 500 mg para cada administración de 6 semanas, particularmente entre 200 y 400 mg para cada administración de 6 semanas. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE comprende progestina en cantidades suficientes como para disminuir el índice de Pearl hasta no más de 1,4, tal como hasta no más de 1,2, 1,0, 0,8, 0,7, 0,6, 0,5, 0,4, 0,3, 0,2 ó 0, 1.<EMI FILE="01010963_1" ID="1" IMF=JPEG >AA male contraceptive formulation CHARACTERIZED BECAUSE it comprises an effective amount of a progestin, where said progestin possesses both androgenic and estrogenic properties. A formulation according to claim 1 CHARACTERIZED BECAUSE the progestin is norethisterone (NET) or its derivatives, such as its carboxylic esters, in particular its acetate or enanthate. A formulation according to claim 1 CHARACTERIZED BECAUSE the levels of said progestin are sufficient to suppress spermatogenesis. A formulation according to claim 1 CHARACTERIZED BECAUSE the levels of said progestin are sufficient to induce oligozoospermia or azoospermia. A formulation according to claim 2 CHARACTERIZED BECAUSE the dose of the NET derivative is between 1 and 10 mg, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg. A formulation according to claim 2 CHARACTERIZED BECAUSE the dose of the NET derivative corresponds to a dose of 100 to 500 mg for each 6-week administration, particularly between 200 and 400 mg for each 6-week administration. A formulation according to claim 1 CHARACTERIZED BECAUSE it comprises progestin in amounts sufficient to decrease the Pearl index to no more than 1.4, such as not more than 1.2, 1.0, 0.8, 0, 7, 0.6, 0.5, 0.4, 0.3, 0.2 or 0, 1. <EMI FILE = "01010963_1" ID = "1" MFI = JPEG> A

CO01010963A 2000-02-15 2001-02-13 MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE CO5261637A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200493 2000-02-15

Publications (1)

Publication Number Publication Date
CO5261637A1 true CO5261637A1 (en) 2003-03-31

Family

ID=37515367

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01010963A CO5261637A1 (en) 2000-02-15 2001-02-13 MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE

Country Status (3)

Country Link
AR (1) AR027526A1 (en)
CO (1) CO5261637A1 (en)
PE (1) PE20011093A1 (en)

Also Published As

Publication number Publication date
PE20011093A1 (en) 2001-10-12
AR027526A1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
GEP20053586B (en) Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same
AR057060A1 (en) TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL
AU7315301A (en) Compounds and compositions for delivering active agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CO5180583A1 (en) ADMINISTRATION OF NON-ORAL ANDROGEN STEROIDS TO WOMEN
NZ600907A (en) Progestin/estradiol transdermal gel
GT200000184A (en) COMPOSITIONS TO FACILITATE THE GROWTH OF SKIN AND METHODS AND ARTICLES THAT USE IT.
MXPA01008611A (en) Compounds and compositions for delivering active agents.
MEP38008A (en) Drospirenone for hormone replacement therapy
RU2011103136A (en) PHARMACEUTICAL COMPOSITION ON THE BASIS OF FINE-GROWED PROGESTERON AND ITS APPLICATIONS
ES2253423T3 (en) FORMULATION OF A TESTOSTERONE ESTER FOR HUMAN USE.
AR031975A1 (en) ANALOG COMPOUNDS OF (1R, CIS) -4- (6-AMINO-9H-PURIN-9-IL) -2-CYCLOPENTENE-1-METHANOL, PROCESS FOR PREPARATION, USE IN THE TREATMENT OF VIRAL INFECTIONS, AND PACKING THAT CONTAINS THEM
AR065816A1 (en) ORAL CONTRACEPTIVE REGIME
AR026655A1 (en) NEW STEROIDS WITH ANDROGENIC ACTIVITY AND ITS USE AS MALE ANTINCONCEPTIVES AND TO TREAT ANDROGENIC INSUFFICIENCY
TW200612962A (en) Estriol and estetrol prodrugs
CO5261637A1 (en) MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
BR0108411A (en) Male contraceptive formulation comprising norethisterone
ES2139602T3 (en) EYE COMPOSITIONS CONTAINING STEROIDS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA.
MX2022000747A (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases.
JP2005532336A5 (en)
PA8474401A1 (en) 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN
AR028699A1 (en) NEW FORMULATION
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
RU2006126632A (en) STEROIDS HAVING A MIXED ANDROGENIC AND PROGRESTAGENIC PROFILE

Legal Events

Date Code Title Description
FA Application withdrawn